Gottschlich A, Grünmeier R, Hoffmann GV, Nandi S, Kavaka V, Müller PJ, Jobst J, Oner A, Kaiser R, Gärtig J, Piseddu I, Frenz-Wiessner S, Fairley SD, Schulz H, Igl V, Janert TA, Di Fina L, Mulkers M, Thomas M, Briukhovetska D, Simnica D, Carlini E, Tsiverioti CA, Trefny MP, Lorenzini T, Märkl F, Mesquita P, Brabenec R, Strzalkowski T, Stock S, Michaelides S, Hellmuth J, Thelen M, Reinke S, Klapper W, Gelebart PF, Nicolai L, Marr C, Beltrán E, Megens RTA, Klein C, Baran-Marszak F, Rosenwald A, von Bergwelt-Baildon M, Bröckelmann PJ, Endres S, Kobold S. Dissection of single-cell landscapes for the development of chimeric antigen receptor T cells in Hodgkin lymphoma. Blood. 2025 Apr 3;145(14):1536-1552. doi: 10.1182/blood.2023022197. JIF20. https://www.sciencedirect.com/science/article/pii/S0006497124114607
Lacher SB, Dörr J, de Almeida GP, Hönninger J, Bayerl F, Hirschberger A, Pedde AM, Meiser P, Ramsauer L, Rudolph TJ, Spranger N, Morotti M, Grimm AJ, Jarosch S, Oner A, Gregor L, Lesch S, Michaelides S, Fertig L, Briukhovetska D, Majed L, Stock S, Busch DH, Buchholz VR, Knolle PA, Zehn D, Dangaj Laniti D, Kobold S*, Böttcher JP*. PGE2 limits effector expansion of tumour-infiltrating stem-like CD8+ T cells. Nature, 2024; May;629(8011):417-425. doi: 10.1038/s41586-024-07254-x. * share senior authorship. JIF 64.8. https://www.nature.com/articles/s41586-024-07254-x
Märkl F, Schultheiß C, Ali M, Chen SS, Zintchenko M, Egli L, Mietz J, Chijioke O, Paschold L, Spajic S, Holtermann A, Dörr J, Stock S, Zingg A, Läubli H, Piseddu I, Anz D, Minden MD, Zhang T, Nerreter T, Hudecek M, Minguet S, Chiorazzi N, Kobold S*, Binder M*. Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia. Nature Communications, 2024; Feb 2;15(1):993. doi: 10.1038/s41467-024-45378-w. * share senior authorship. JIF 17. https://www.nature.com/articles/s41467-024-45378-w
Wagenbauer KF, Pham N, Gottschlich A, Kick B, Kozina V, Frank C, Trninic D, Stömmer P, Grünmeier R, Carlini E, Tsiverioti CA, Kobold S*, Funke JJ*, Dietz H*. Programmable multispecific DNA-origami-based T-cell engagers. Nat Nanotechnology, 2023; Nov;18(11):1319-1326. doi: 10.1038/s41565-023-01471-7. * share senior authorship. JIF40. https://www.nature.com/articles/s41565-023-01471-7
- Gottschlich A, Thomas M, Grünmeier R, Lesch S, Rohrbacher L, Igl V, Briukhovetska D, Benmebarek MR, Vick B, Dede S, Müller K, Xu T, Dhoqina D, Märkl F, Robinson S, Sendelhofert A, Schulz H, Umut Ö, Kavaka V, Tsiverioti Ch, Carlini E, Nandi S, Strzalkowski T, Lorenzini T, Stock S, Müller P, Dörr J, Seifert M, Cadilha B, Brabenec R, Röder N, Rataj F, Nüesch M, Modemann F, Wellbrock J, Fiedler W, Kellner Ch, Beltrán E, Herold T, Paquet D, Jeremias I, von Baumgarten L, Endres S, Subklewe M, Marr C, Kobold S. (2023). Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia. Nature Biotechnology, 41 (11), 1618-1632. doi:10.1038/s41587-023-01684-0. JIF2022=68,2. https://pubmed.ncbi.nlm.nih.gov/36914885/
- Briukhovetska, D., Suarez-Gosalvez, J., Voigt, C., Markota, A., Giannou, A. D., Schubel, M., Jobst, J., Zhang, T., Dorr, J., Markl, F., Majed, L., Muller, P. J., May, P., Gottschlich, A., Tokarew, N., Lucke, J., Oner, A., Schwerdtfeger, M., Andreu-Sanz, D., Grunmeier, R., Seifert, M., Michaelides, S., Hristov, M., Konig, L. M., Cadilha, B. L., Mikhaylov, O., Anders, H. J., Rothenfusser, S., Flavell, R. A., Cerezo-Wallis, D., Tejedo, C., Soengas, M. S., Bald, T., Huber, S., Endres, S., & Kobold, S. (2023). T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis. Immunity, 56(1), 143-161 e111. doi:10.1016/j.immuni.2022.12.010. JIF2021=43,4. https://pubmed.ncbi.nlm.nih.gov/36630913/
- Briukhovetska, D., Dorr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021). Interleukins in cancer: from biology to therapy. Nature Reviews Cancer, 21(8), 481-499. doi:10.1038/s41568-021-00363-z. JIF2021=69,8. https://pubmed.ncbi.nlm.nih.gov/34083781/
- Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha B, Dantes Z, Rataj F, Dorman K, Lutz J, Karches C, Heise C, Kurzay M, Larimer B, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth Ch, Benmebarek MR, Dhoqina D, Gruenmeier R, Seifert M, Oener A, Umut Ö, . . . Rothenfusser S, Duewell P, Koenig L, Schnurr M, Subklewe M, Liss A, Halama N, Reichert M, Mempel T, Endres S, Kobold S. (2021). T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nature Biomedical Engineering, 5 (11), 1246-1260. doi:10.1038/s41551-021-00737-6. JIF2021=29,23. https://www.nature.com/articles/s41551-021-00737-6
- Cadilha B, Benmebarek MR, Dorman K, Oener A, Lorenzini T, Obeck H, Väntinnen M, Di Pilato M, Pruessmann JN, Stoiber S, Huynh D, Maerkl F, Seifert M, Manske K, Suarez-Gosalvez J, Zeng Y, Lesch S, Karches CH, Heise C, Gottschlich A, Thomas M, Marr C, Zhang J, Pandey D, Feuchtinger T, Subklewe M, Mempel TR, Endres S, Kobold S. (2021). Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumor. Science Advances, 7 (24). doi:10.1126/sciadv.abi5781. JIF2022=13,6. https://pubmed.ncbi.nlm.nih.gov/34108220/
- Benmebarek MR, Cadilha B, Hermman M, Lesch S, Schmitt S, Stoiber S, Darwich A, Augsberger Ch, Brauchle B, Rohrbacher L, Oener A, Seifert M, Schwerdtfeger M, Gottschlich A, Rataj F, Fenn NC, Klein Ch, Subklewe M, Endres S, Hopfner KP, Kobold S. (2021). A modular and controllable T cell therapy platform for acute myeloid leukemia. Leukemia, 35, 2243-2257. JIF2021=12,88. https://pubmed.ncbi.nlm.nih.gov/33414484/
- Di Pilato M*, Kfuri-Rubens R*, Pruessmann J*, Ozga AJ*, Messemaker, M, Cadilha B, Sivakumar R, Cianciaruso Ch, Warner RD, Marangoni F, Carrizosa E, Lesch S, Billingsley J, Perez-Ramos D, Zavala F, Rheinbay E, Luster AD, Gerner MY, Kobold S, Pittet MJ, Mempel TR. (2021). CXCR6 positions cytotoxic T cells to receive critical survival signals in the tumor microenvironment. Cell, 184 (17), 4512-4530. *contributed equally. doi:10.1016/j.cell.2021.07.015. JIF2022=66,85. https://www.sciencedirect.com/science/article/abs/pii/S0092867421008564?dgcid=co author
Liu X, Li J, Cadilha B, Markota A, Voigt C, Huang Z, Lin P, Wang D, Juncheng D, Kranz G, Krandick A, Libl D, Zitzelsberger H, Zagorski I, Braselmann H, Pan M, Zhu S, Huang Y, Niedermeyer S, Reichel Ch, Uhl B, Briukhovetska D, Suarez Gosalvez J, Kobold S, Gires O, Wang H. (2019). Epithelial-type systemic breast carcinoma cells with a restricted mesenchymal transition are a major source of metastasis. Science Advances, 5 (6), eaav4275.doi:10.1126/sciadv.aav4275. JIF2022=13,6. https://pubmed.ncbi.nlm.nih.gov/31223646/
Ferrari de Andrade, L., Tay, R. E., Pan, D., Luoma, A. M., Ito, Y., Badrinath, S., Tsoucas, D., Franz, B., May, K. F., Jr., Harvey, C. J., Kobold, S., Pyrdol, J. W., Yoon, C., Yuan, G. C., Hodi, F. S., Dranoff, G., & Wucherpfennig, K. W. (2018). Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell-driven tumor immunity. Science, 359(6383), 1537-1542. doi:10.1126/science.aao0505. JIF2021=47,73. https://pubmed.ncbi.nlm.nih.gov/29599246/
Voigt C*, May P*, Gottschlich A*, Markota A, Wenk D, Gerlach I, Voigt S, Stathopoulos GT, Arendt K, Heise C, Rataj F, Janssen KP, Königshoff M, Winter H, Himsl I, Thasler W, Schnurr M, Rothenfußer S, Endres S, Kobold S. (2017). Cancer cells induce interleukin-22 production from memory CD4+ T cells via interleukin-1 to promote tumor growth. Proceedings of the National Academy of Sciences. 114 (49), 12994-12999. *contributed equally. doi:10.1073/pnas.1705165114. JIF2021=12,77. https://pubmed.ncbi.nlm.nih.gov/29150554/
Kobold* S, Grassmann* S, Chaloupka M, Lampert C, Wenk S, Kraus F, Rapp M, Duewell P, Zeng Y, Schmollinger J, Schnurr M, Endres S#, Rothenfußer S#. (2015). Impact of a new fusion receptor on PD-1-mediated immunosuppression in adoptive T cell therapy. The Journal of the National Cancer Institute, 107. *contributed equally to this study, # share senior authorship. JIF2021=11,81. http://www.ncbi.nlm.nih.gov/pubmed/26105028
Kobold S, Steffen J, Chaloupka M, Grassmann S, Henkel J, Castoldi R, Zeng Y, Chmielewski M, Schmollinger J, Schnurr M, Rothenfußer S, Schendel DJ, Abken H, Sustmann C, Niederfellner CG, Klein C, Bourquin C, Endres S. (2014). Selective bispecific T cell recruiting antibody enhances anti-tumor activity of adoptive T cell transfer. The Journal of the National Cancer Institute. 107:364. JIF2021=11,81. https://pubmed.ncbi.nlm.nih.gov/25424197/
Kobold S, Völk S, Clauditz T, Küpper NJ, Minner S, Tufmann A, Düwell P, Lindner M, Koch I, Heidegger S, Merk M, Rothenfußer S, Schnurr M, Huber RM, Sauter G, Wilczak W, Endres S. (2013). Interleukin-22 is frequently expressed in small-and large- cell lung cancer and promotes growth in chemotherapy-resistant cancer cells. Journal of Thoracic Oncology, 8:1032-1042. JIF2021=20,12. https://pubmed.ncbi.nlm.nih.gov/23774470/
Prof. Dr. med. Sebastian KoboldInstitut für Klinische PharmakologieProject Management
Simone Gautier, M.A., M.E.U.SProject Management089 4400-57320
Dr. rer. nat. Kerstin AlthausProject Manager IOLIN
Dr. rer. nat. Rosa Elena Andrade AguirreProject Manager BAYCELLatorTechnical Assistants - Labor
Susanne WenkCTA
Disha ShahTA (since 2025)
Weronika SzulejkoTA (since 2025)
Sayantan Nandi, Ph. D.Research Assistent (since 2022)Post-Docs
Dr. rer. nat. Daria BriukhovetskaPost-Doc (since 2018)
Dr. med. Adrian GottschlichPost-Doc (since 2019)
Dr. med. Sophia Stock, MHBAPost-Doc (since 2021)
Dr. rer. nat. Donjete SimnicaPost-Doc, funded by Walter-Benjamin Fellowships, active since 2022
Dr. med. Ngoc-Thien-Thu NguyenPost-Doc. IOLIN
Janina Dörr, Ph. D.Post-Doc. BZKF Young Scientist Fellow
Arman ÖnerPost-Doc
Dr. phil. Marcel TrefnyPost-Doc. Marie Curie Fellowship
Stefanos MichaelidesPost-Doc. IOLIN (since 2025)
Dr. med. Tengis TschaidsePost-Doc. IOLIN (since 2025)
Dr. Bernhard Ransmayr
Natasha Samson, Ph. D.Post-Doc. Marie Curie Fellowship
Emanuele Carlini, M. Sc.Doctoral Researcher (PhD track), T-OP - (seit 2021)Doctoral Researchers
David Andreu Sanz, M. Sc.Doctoral researcher (PhD track), T-OP - (seit 2021)
Mara HenrichDoctoral Researcher. LETSimmun CRC TRR 338. (PhD track) (since 2023)
Philipp Jie MüllerDoctoral researcher (MD track). Deutsche Krebshilfe - (seit 2021)
Vivien MenkhoffDoctoral Researcher (MD track, FöFoLe) (since 2023)
Emre ErdoganDoctoral researcher (PhD track, BAYCELLator - Bayerische Transformations und Forschungsstiftung) (since 2023)
Rasmus MüllerDoctoral researcher (MD track) (since 2023)
Charlotte CarcopinoDoctoral researcher (PhD track, BAYCELLator, Bayerische Transformations und Forschungsstiftung) (since 2023)
Jakob HarwoodDoctoral researcher (PhD track) (since 2024)
Thomas JanertDoctoral researcher. FöFoLe (MD track) (since 2024)
Seoyoung JangDoctoral researcher. MD track - Deutschlandstipendium (since 2024)
Kathrin GabrielDoctoral researcher (PhD track) Stiftung der Deutschen Wirtschaft (since 2024)
Wendy den HartogDoctoral researcher (PhD track) (since 2024)
Anna BöhmDoctoral researcher (MD track) (since 2024)
Lilli BallheimerDoctoral researcher (MD track) (since 2025)
Jana EngesserDoctoral researcher (MD track) FöFoLe (since 2025)
Mara Rachel ManieriDoctoral researcher (MD track) FöFoLe (since 2025)
Philipp Daniel PenoviciDoctoral researcher (MD track) FöFoLe (since 2025)
Simon DelahaisDoctoral researcher (PhD track. Stipendium: Bayerische Transformations und Forschungsstiftung) (since 2025)
Naima GierlichsDoctoral researcher (MD track) Deutsche Krebshilfe (since 2025)
Philipp SchnellDoctoral researcher (MD track, since 2025)
Leïla Munaretto, M.Sc.Doctoral researcher (PhD track, Marie Skłodowska-Curie program T-RAFIC ) (since 2025)
Iona Elisabeth KlepserDoctoral Researcher (MD track) funded by the Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO), active since 2025.
Martina de VizioDoctoral researcher (PhD track) (since 2025)